The biomarker‐based diagnostic profile of 4RT was determined by lower p‐tau181 levels than AD (< 56 pg/mL) in combination with high basal ganglia (pallidum) tau binding (DVR > 1), but t‐tau and perfusion did not add additional discriminatory value in 4RTs. This evidence concerns the gene MAPT and Alzheimer disease.